Postpartum cardiomyopathy, more precisely called peripartum cardiomyopathy (PPCM), is a form of heart failure that develops during the last month of pregnancy or within the first five months after delivery. It affects roughly 1 in every 2,230 births in the United States, and mortality estimates range from 3% to as high as 40% depending on the population studied and how quickly it’s caught. The condition weakens the heart muscle, reducing its ability to pump blood effectively at a time when most people assume the hard part is over.
How It Differs From Normal Postpartum Symptoms
This is the core problem with PPCM: its early symptoms look a lot like the normal discomforts of late pregnancy and early postpartum life. Swollen feet and ankles, shortness of breath, fatigue. In a mild case, these overlap so closely with typical third-trimester complaints that the condition often goes undiagnosed initially.
The red flags that separate PPCM from ordinary postpartum recovery include shortness of breath that worsens when lying flat, swelling that persists or gets worse well after delivery, a rapid or irregular heartbeat, dizziness, and chest pressure. If you’re weeks postpartum and find yourself more winded climbing stairs than you were at nine months pregnant, that’s the kind of mismatch worth raising with a doctor. Fewer than 10% of cases develop before delivery; the vast majority show up in the first four months after birth.
What Happens Inside the Heart
A healthy heart pumps out about 55% to 70% of the blood in its main chamber with each beat, a measurement called the ejection fraction. PPCM is diagnosed when that number drops below 45% and the heart chamber enlarges, with no other identifiable cause of heart disease present. In women who carry a specific genetic variant, the ejection fraction at diagnosis can be even lower, averaging around 23% to 24% compared with 29% in women without the variant.
One of the most studied biological pathways involves prolactin, the hormone responsible for milk production. Prolactin normally supports the growth of tiny blood vessels. In PPCM, an enzyme released from stressed heart cells clips prolactin into a smaller fragment that does the opposite: it destroys the blood vessels feeding the heart muscle. The result is a heart starved of its own blood supply. This discovery is why a medication that blocks prolactin release has been tested as a treatment, with promising early results.
Who Is Most at Risk
Several factors raise the likelihood of developing PPCM:
- Advanced maternal age: women over 30, and especially over 35, face higher risk.
- African descent: Black women are disproportionately affected, both in incidence and severity.
- Multiple gestation: carrying twins or higher-order multiples puts extra strain on the heart.
- Preeclampsia: a history of high blood pressure during pregnancy is a significant risk factor.
- Diabetes and low socioeconomic status: both independently increase risk.
Genetics also play a role. About 10% of women with PPCM carry mutations in the gene that produces titin, a giant protein that acts like a molecular spring inside heart muscle cells. Women with these mutations are roughly nine times more likely to develop PPCM than the general population, and they tend to present with more severely reduced heart function. Having a first-degree relative with any form of cardiomyopathy is worth mentioning to your care team during pregnancy.
How It’s Diagnosed
An echocardiogram, essentially an ultrasound of the heart, is the primary diagnostic tool. Doctors look for an ejection fraction below 45%, an enlarged heart chamber, or both. The diagnosis also requires ruling out other causes of heart failure, such as preexisting valve disease or a congenital heart condition that was never detected.
Because the early symptoms mimic normal pregnancy complaints, diagnosis is frequently delayed. If shortness of breath, rapid heart rate, or worsening swelling develop in the weeks after delivery, pushing for an echocardiogram is reasonable. Early detection significantly improves outcomes.
Treatment and Recovery
Standard heart failure medications form the backbone of treatment. These typically include drugs that reduce the heart’s workload, control fluid retention, and slow the heart rate to let it pump more efficiently. Some of these medications are not safe during pregnancy or breastfeeding, which means the treatment plan depends partly on timing.
Bromocriptine, the prolactin-blocking medication, has shown real promise in early trials. In one study, women who received it alongside standard heart failure therapy had significantly better heart function recovery at six months compared with women on standard therapy alone. It’s not yet universally adopted, but it represents a treatment approach specific to PPCM rather than borrowed from general heart failure care. One trade-off: because bromocriptine suppresses prolactin, it stops milk production, meaning breastfeeding isn’t possible during treatment.
Recovery varies widely. Many women see their heart function return to normal, but the timeline can stretch over months. After the heart recovers, expert guidance suggests continuing medications for at least a year before slowly tapering them, with echocardiograms every three to six months during the weaning process. Even women whose hearts fully recover should continue seeing a cardiologist annually.
What This Means for Future Pregnancies
The question of whether it’s safe to get pregnant again after PPCM is one of the most consequential decisions women face. The risk of recurrence is real, but it depends heavily on whether the heart fully recovered before the next pregnancy.
In women whose ejection fraction normalized (back to 50% or above) before becoming pregnant again, the recurrence rate was about 23%. For women whose heart function remained impaired, that rate jumped to 48%. A large prospective study found that women with fully recovered function (ejection fraction of 55% or higher) had a meaningful reduction in heart failure relapse during a subsequent pregnancy, though the risk never drops to zero.
Long-term follow-up data paint a starker picture for women with persistent dysfunction: after five years, 53% of those who entered a subsequent pregnancy with reduced heart function experienced adverse outcomes, and the mortality rate in that group was about 13%. Women who had fully recovered fared far better, with a 20% adverse outcome rate over the same period. Close monitoring throughout any subsequent pregnancy and for six months afterward, with serial echocardiograms, is the standard approach.